Shopping Cart
Remove All
Your shopping cart is currently empty
PI-55 (6-(2-hydroxy-3-methylbenzylamino)purine) is a cytokinin receptor inhibitor that exhibits structural similarity to 6-benzylaminopurine (BAP). It competitively inhibits BAP binding on the specific Arabidopsis receptors CRE1/AHK4 and AHK3. Furthermore, PI-55 effectively suppresses cytokinins-induced haustorium formation and enhances parasite aggressiveness [1].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $113 | In Stock | In Stock | |
| 5 mg | $297 | In Stock | In Stock | |
| 10 mg | $448 | In Stock | In Stock | |
| 25 mg | $768 | In Stock | In Stock | |
| 50 mg | $1,070 | In Stock | In Stock | |
| 100 mg | $1,380 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $327 | In Stock | In Stock |
| Description | PI-55 (6-(2-hydroxy-3-methylbenzylamino)purine) is a cytokinin receptor inhibitor that exhibits structural similarity to 6-benzylaminopurine (BAP). It competitively inhibits BAP binding on the specific Arabidopsis receptors CRE1/AHK4 and AHK3. Furthermore, PI-55 effectively suppresses cytokinins-induced haustorium formation and enhances parasite aggressiveness [1]. |
| In vitro | High concentrations of PI-55 (10 μM and 100 μM) result in partial inhibition of early haustorial structure development, particularly in the presence of cytokinin. Further, PI-55 treatment, when combined with BAP, diminishes the virulence of P. ramosa compared to the application of BAP alone. This suggests the involvement of histidine kinase receptors analogous to CRE1/AHK4 and AHK3 in the signaling pathway that initiates early haustorial formation [1]. |
| Synonyms | 6-(2-hydroxy-3-methylbenzylamino)purine |
| Molecular Weight | 255.28 |
| Formula | C13H13N5O |
| Cas No. | 1122579-42-3 |
| Smiles | Cc1cccc(CNc2ncnc3[nH]cnc23)c1O |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 5.83 mg/mL (22.84 mM), Sonication is recommended. | |||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (3.92 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.